Compugen Announces Preeclampsia Biomarker Collaboration

Collaboration Based on Compugen Discovered VEGF Receptor Splice Variant

10-Nov-2009 - Compugen Ltd. announced that it has signed a research and license agreement with a diagnostic company covering CGEN-226, a biomarker candidate for early detection of preeclampsia. Preeclampsia is the most common of the dangerous pregnancy complications, occurring in 5-8% of all pregnancies, with ...

Medarex and Compugen Announce Therapeutic Antibody Co-Development Agreement

25-Jan-2007 - Medarex, Inc. and Compugen Ltd. have entered into a collaborative agreement to develop novel monoclonal antibody-based therapeutics for oncology and autoimmune diseases. Under the terms of the agreement, Medarex and Compugen plan to share discovery, development and commercialization ...

Compugen Appoints Eli Zangvil, MD, as Vice President Business Development

13-Nov-2006 - Compugen Ltd. announced the appointment of Eli Zangvil, MD, as Vice President, Business Development. In this position, Dr. Zangvil will join the Commercial Operations team with management responsibility for selected strategic alliance and business development activities. In his role, Dr. Zangvil ...

Compugen Leads Consortium to Model Cancer Related Kinase Pathway

European Commission to Fund SIMAP Consortium

10-Mar-2006 - Compugen Ltd. announced that it is leading a consortium for the development of a platform to simulate the MAP-kinase pathway, a signaling pathway related to cancer which is already targeted by a number of cancer therapies and diagnostic tests. The Simulation Modeling of the MAP-kinase Pathway ...

Compugen Announces Diagnostic Biomarker Collaboration

10-Jun-2005 - Compugen Ltd. announced a collaboration agreement with Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company, for the development and commercialization of immunoassay diagnostic markers. Under the agreement, Ortho-Clinical Diagnostics and Compugen will jointly develop diagnostic products ...

Evogene Appoints Ofer Haviv as President and CEO

01-Jun-2005 - Evogene announced the appointment of Ofer Haviv as President and Chief Executive Officer. Previously, Haviv was the Company's Chief Operating and Financial Officer. Dr Hagai Karchi, who co-founded Evogene in 2002 with Dr Rafi Meissner and has served as CEO since that time, has been appointed ...

Compugen and Tel Aviv University Announce Unique Predictive Method for Identifying Alternative Splicing in the Human Genome

New method does not require EST or microarray data - Hundreds of novel proteins found to date

28-Oct-2004 - Compugen Ltd. and Tel Aviv University announced the development of a new method for identifying alternative splicing without the need for either EST (Expressed Sequence Tag) data or microarray experimentation. Hundreds of novel predicted proteins discovered to date using this new predictive ...

Compugen Announces Discovery of Abundant RNA Editing Sites in the Human Transcriptome

Findings published in Nature Biotechnology

20-Jul-2004 - Tel Aviv, Israel: Compugen Ltd. announced the systematic identification of adenosine to inosine (A to I) RNA editing sites in the human transcriptome, increasing the number of known A to I editing sites from approximately 100 to more than 10,000. The discovery is being published in Nature ...

Compugen Establishes Small Molecule Drug Discovery Subsidiary

06-Jul-2004 - Compugen Ltd. announced the establishment of a new subsidiary, Keddem Bioscience Ltd., focused on small molecule drug discovery. The program now being transferred to the new company was initiated in 2000 as the chemistry division of Compugen. The subsidiary's offices and laboratories are located ...